Shares of Mind Medicine Inc. (MNMD) surged more than 15% Friday afternoon, on track for their best session since April 2024, ...

Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT Business Wire • last month MindMed Scientific Presentations at American College of ...

Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the promising potential of Mind Medicine’s MM120 treatment. The company is advancing MM120, a ...

Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide D-tartrate (LSD), MM120 orally disintegrating tablets (ODT), for the ...

MM120 ODT uses Catalent’s Zydis ODT technology. Credit: MindMed Inc./Business Wire. Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of ...

The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants.

Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 ...